Lesovaya, Ekaterina <br/><br/>
Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.  [electronic resource] 

 -  Cell cycle (Georgetown, Tex.)  Jan 2013 
 - 133-44 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1551-4005 
<br/><br/><label>Standard No.: </label>10.4161/cc.23048  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Apoptosis--drug effects<br/>Boronic Acids--therapeutic use<br/>Bortezomib<br/>Cell Line, Tumor<br/>Dexamethasone--toxicity<br/>Dimerization<br/>Drug Synergism<br/>Hematologic Neoplasms--drug therapy<br/>Humans<br/>K562 Cells<br/>Lymphoma--drug therapy<br/>NF-kappa B--antagonists & inhibitors<br/>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Proteasome Inhibitors--therapeutic use<br/>Pyrazines--therapeutic use<br/>RNA Interference<br/>RNA, Small Interfering--metabolism<br/>Receptors, Glucocorticoid--agonists<br/>Transcription Factor AP-1--antagonists & inhibitors<br/>Transcriptional Activation<br/>Triazoles--therapeutic use<br/>Tumor Cells, Cultured